The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Global sectoral equity funds also saw a net $258 million worth of sales, the first weekly outflow in six weeks. Consumer ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Today, Benzinga's options scanner spotted 9 options trades for AstraZeneca. This isn't normal. The overall sentiment of these ...